Johnson et al. confirmed that HLA class-II expression on tumor cells identified by immunohistochemistry was associated with clinical response, PFS, and OS in melanoma patients treated with anti-PD-1, as well as with CD4+ and CD8+ tumor infiltrate [17]. Here, CD8A is linked to melanoma.